Parvovirus B19 infection in pediatric allogeneic hematopoietic cell transplantation - Single-center experience and review.

Malcolm HolterhusMarc HenniesHartmut HillmannHeike ThorerClaudia RossigBirgit BurkhardtAndreas H Groll

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2023)

Symptomatic B19V infection following HCT remains a rare but potentially challenging complication. A causal antiviral therapy does not exist as well as general recommendations on dosage and duration of IVIG therapy. Despite this, most patients are treated successfully with these measures. Additionally, transmission via blood or stem cell products is also rare and no general recommendations on B19V screenings exist.

Keyphrases

stem cells
newly diagnosed
end stage renal disease
ejection fraction
stem cell transplantation
clinical practice
prognostic factors
bone marrow
low dose
patient reported outcomes